4061 Clinical utility of precision medicine approaches to guide anti-platelet selection for adult patients with acute coronary syndromes (ACS), following percutaneous coronary intervention (PCI)
OBJECTIVES/GOALS: Our goal is to determine if a precision medicine approach to guide anti-platelet therapy for patients with ACS, post PCI, is feasible for a diverse urban population. Also, we will evaluate if guided therapy reduces major adverse cardiovascular events (MACE) while remaining economic...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2020-06-01
|
| Series: | Journal of Clinical and Translational Science |
| Online Access: | https://www.cambridge.org/core/product/identifier/S2059866120003283/type/journal_article |
| _version_ | 1811155103033327616 |
|---|---|
| author | Scott Mosley Samantha Yeung David Shavelle Leonardo Clavijo Tien Ng |
| author_facet | Scott Mosley Samantha Yeung David Shavelle Leonardo Clavijo Tien Ng |
| author_sort | Scott Mosley |
| collection | DOAJ |
| description | OBJECTIVES/GOALS: Our goal is to determine if a precision medicine approach to guide anti-platelet therapy for patients with ACS, post PCI, is feasible for a diverse urban population. Also, we will evaluate if guided therapy reduces major adverse cardiovascular events (MACE) while remaining economically sustainable. METHODS/STUDY POPULATION: This prospective, pragmatic study will enroll two-hundred patients with ACS undergoing PCI, receiving DAPT. Patients will receive point-of-care CYP2C19 genotyping. Patients with at least one loss-of-function (LoF) allele will be recommended prasugrel. Those without LoF alleles, will be recommended to take prasugrel for 7 days then clopidogrel for 7 days, followed with platelet reactivity phenotyping. Patients with HPR >208 P2Y12 reaction units will take prasugrel; the remainder will take clopidogrel. We will review electronic health records and contact patients at baseline, then at 1, 3, 6, and 12 months to collect data for cardiovascular and health-related quality of life (HRQoL) outcomes. RESULTS/ANTICIPATED RESULTS: Feasibility and clinical utility will be measured by the proportion of patients with a genotype or phenotype leading to a clinical recommendation of alternative therapy and whether or not recommendations were accepted by clinicians. Effectiveness will be measured by combined MACE (composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke), stent thrombosis, and major and minor bleeding over the study period. Cost of testing, 30-day hospital readmission, and HRQoL questionnaires will be included for pharmacoeconomic analysis from an institutional perspective. DISCUSSION/SIGNIFICANCE OF IMPACT: There are no studies investigating the clinical utility of implementing guided anti-platelet selection, combining CYP2C19 genotyping and HPR phenotyping. We anticipate incorporating this precision medicine approach to guide P2Y12 inhibitor selection will be feasible while improving patient outcomes. |
| first_indexed | 2024-04-10T04:27:18Z |
| format | Article |
| id | doaj.art-7184bf703c8245638ab4414cadc89767 |
| institution | Directory Open Access Journal |
| issn | 2059-8661 |
| language | English |
| last_indexed | 2024-04-10T04:27:18Z |
| publishDate | 2020-06-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | Journal of Clinical and Translational Science |
| spelling | doaj.art-7184bf703c8245638ab4414cadc897672023-03-10T08:51:36ZengCambridge University PressJournal of Clinical and Translational Science2059-86612020-06-01410610710.1017/cts.2020.3284061 Clinical utility of precision medicine approaches to guide anti-platelet selection for adult patients with acute coronary syndromes (ACS), following percutaneous coronary intervention (PCI)Scott Mosley0Samantha Yeung1David Shavelle2Leonardo Clavijo3Tien Ng4University of Southern California School of PharmacyUniversity of Southern California School of PharmacyKeck School of Medicine at University of Southern CaliforniaKeck School of Medicine at University of Southern CaliforniaUniversity of Southern California School of PharmacyOBJECTIVES/GOALS: Our goal is to determine if a precision medicine approach to guide anti-platelet therapy for patients with ACS, post PCI, is feasible for a diverse urban population. Also, we will evaluate if guided therapy reduces major adverse cardiovascular events (MACE) while remaining economically sustainable. METHODS/STUDY POPULATION: This prospective, pragmatic study will enroll two-hundred patients with ACS undergoing PCI, receiving DAPT. Patients will receive point-of-care CYP2C19 genotyping. Patients with at least one loss-of-function (LoF) allele will be recommended prasugrel. Those without LoF alleles, will be recommended to take prasugrel for 7 days then clopidogrel for 7 days, followed with platelet reactivity phenotyping. Patients with HPR >208 P2Y12 reaction units will take prasugrel; the remainder will take clopidogrel. We will review electronic health records and contact patients at baseline, then at 1, 3, 6, and 12 months to collect data for cardiovascular and health-related quality of life (HRQoL) outcomes. RESULTS/ANTICIPATED RESULTS: Feasibility and clinical utility will be measured by the proportion of patients with a genotype or phenotype leading to a clinical recommendation of alternative therapy and whether or not recommendations were accepted by clinicians. Effectiveness will be measured by combined MACE (composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke), stent thrombosis, and major and minor bleeding over the study period. Cost of testing, 30-day hospital readmission, and HRQoL questionnaires will be included for pharmacoeconomic analysis from an institutional perspective. DISCUSSION/SIGNIFICANCE OF IMPACT: There are no studies investigating the clinical utility of implementing guided anti-platelet selection, combining CYP2C19 genotyping and HPR phenotyping. We anticipate incorporating this precision medicine approach to guide P2Y12 inhibitor selection will be feasible while improving patient outcomes.https://www.cambridge.org/core/product/identifier/S2059866120003283/type/journal_article |
| spellingShingle | Scott Mosley Samantha Yeung David Shavelle Leonardo Clavijo Tien Ng 4061 Clinical utility of precision medicine approaches to guide anti-platelet selection for adult patients with acute coronary syndromes (ACS), following percutaneous coronary intervention (PCI) Journal of Clinical and Translational Science |
| title | 4061 Clinical utility of precision medicine approaches to guide anti-platelet selection for adult patients with acute coronary syndromes (ACS), following percutaneous coronary intervention (PCI) |
| title_full | 4061 Clinical utility of precision medicine approaches to guide anti-platelet selection for adult patients with acute coronary syndromes (ACS), following percutaneous coronary intervention (PCI) |
| title_fullStr | 4061 Clinical utility of precision medicine approaches to guide anti-platelet selection for adult patients with acute coronary syndromes (ACS), following percutaneous coronary intervention (PCI) |
| title_full_unstemmed | 4061 Clinical utility of precision medicine approaches to guide anti-platelet selection for adult patients with acute coronary syndromes (ACS), following percutaneous coronary intervention (PCI) |
| title_short | 4061 Clinical utility of precision medicine approaches to guide anti-platelet selection for adult patients with acute coronary syndromes (ACS), following percutaneous coronary intervention (PCI) |
| title_sort | 4061 clinical utility of precision medicine approaches to guide anti platelet selection for adult patients with acute coronary syndromes acs following percutaneous coronary intervention pci |
| url | https://www.cambridge.org/core/product/identifier/S2059866120003283/type/journal_article |
| work_keys_str_mv | AT scottmosley 4061clinicalutilityofprecisionmedicineapproachestoguideantiplateletselectionforadultpatientswithacutecoronarysyndromesacsfollowingpercutaneouscoronaryinterventionpci AT samanthayeung 4061clinicalutilityofprecisionmedicineapproachestoguideantiplateletselectionforadultpatientswithacutecoronarysyndromesacsfollowingpercutaneouscoronaryinterventionpci AT davidshavelle 4061clinicalutilityofprecisionmedicineapproachestoguideantiplateletselectionforadultpatientswithacutecoronarysyndromesacsfollowingpercutaneouscoronaryinterventionpci AT leonardoclavijo 4061clinicalutilityofprecisionmedicineapproachestoguideantiplateletselectionforadultpatientswithacutecoronarysyndromesacsfollowingpercutaneouscoronaryinterventionpci AT tienng 4061clinicalutilityofprecisionmedicineapproachestoguideantiplateletselectionforadultpatientswithacutecoronarysyndromesacsfollowingpercutaneouscoronaryinterventionpci |